Meredith Blount is a Counsel in the firm’s Corporate Group and specializes in corporate, securities and business law for emerging growth companies in the technology and life science sectors. Meredith counsels clients on start-up and formation matters, corporate governance, seed and venture capital financing, public offerings, M&A, licensing, and other general corporate matters in the industries of pharmaceuticals, medical devices and diagnostics, biotechnology, digital media, social media and e-commerce among others.

Meredith has represented C-level executives and boards of directors of leading biotech, digital media, internet, e-commerce, and social media companies on public financings, venture capital financings, buy- and sell-side mergers and acquisitions, start-up/formation, and corporate governance, and has led and managed corporate restructurings, and managed and closed domestic and international (Spain, Brazil, Sweden, India, Australia, the Netherlands) equity and debt financings, and M&A transactions, including drafting and negotiating all transactional documents, building financial payout models, conducting due diligence, and managing state and federal securities compliance. Meredith has also acted as investors’ and underwriters’ counsel in connection with private and public financings.

Meredith began her legal career in the New York office of Gunderson Dettmer LLP, one of the nation’s premier business law firms for emerging growth companies, and went on to practice in the Life Sciences group at Goodwin Procter LLP, which is consistently ranked one of the best biotech law firms in the country.

Education

  • J.D., Vanderbilt University School of Law
  • M.S.F., Owen Graduate School of Management at Vanderbilt University
  • B.A., University of Miami School of Business